Evidence map›Paper›PMID 37274050›Full record

ArticleWorld journal of clinical cases2023

Intestinal complications in patients with Crohn's disease in the Brazilian public healthcare system between 2011 and 2020.

Ligia Yukie Sassaki, Adalberta Lima Martins, Rodrigo Galhardi-Gasparini, Rogerio Saad-Hossne, Alessandra Mileni Versut Ritter, Tania Biatti Barreto, Taciana Marcolino, Bruno Balula, Claudia Yang-Santos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical cases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ligia Yukie SassakiDepartment of Internal Medicine, São Paulo State University - UNESP, Medical School, 18618687, Botucatu, Brazil.
Adalberta Lima MartinsDepartment of Gastroenterology, State Office for Pharmaceutical Assistance at Espírito Santo Health Office, Vitoria 29017-010, Espirito Santo, Brazil.
Rodrigo Galhardi-GaspariniDepartment of Gastroenterology, SETE - Specialized Medical Center, Marilia 17502-020, Sao Paulo, Brazil.
Rogerio Saad-HossneDepartment of Surgery, São Paulo State University - UNESP, Medical School, 18618687, Botucatu, Brazil.
Alessandra Mileni Versut RitterReal World Evidence, IQVIA Brazil, 04719-002, Sao Paulo, Brazil.
Tania Biatti BarretoMedical Affairs, Takeda Pharmaceuticals Brazil, 04794-000, Sao Paulo, Brazil.
Taciana MarcolinoMedical Affairs, Takeda Pharmaceuticals Brazil, 04794-000, Sao Paulo, Brazil.
Bruno BalulaReal World Evidence, IQVIA Brazil, 04719-002, Sao Paulo, Brazil.
Claudia Yang-SantosClinical Research, Takeda Pharmaceuticals Brazil, 04794-000, Sao Paulo, Brazil. clausantos2910@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis is a secondary database study using the Brazilian public healthcare system database.

aimTo describe intestinal complications (ICs) of patients in the Brazilian public healthcare system with Crohn's disease (CD) who initiated and either only received conventional therapy (CVT) or also initiated anti-tumor necrosis factor (anti-TNF) therapy between 2011 and 2020.

methodsThis study included patients with CD [international classification of diseases - 10

resultsIn the 16809 patients with CD that met the inclusion criteria, the mean follow-up duration was 4.44 (2.37) years. In total, 14697 claims of ICs were found from 4633 patients. Over the 1- and 5-year of follow-up, 8.3% and 8.2% of the patients with CD, respectively, presented at least one IC, of which fistula (31%) and fistulotomy (48%) were the most commonly reported. The overall incidence rate (95%CI) of ICs was 6.8 (6.5-7.04) per 100 patient years for patients using only-CVT, and 9.2 (8.8-9.6) for patients with evidence of anti-TNF therapy.

conclusionThe outcomes highlighted an important and constant rate of ICs over time in all the CD populations assessed, especially in patients exposed to anti-TNF therapy. This outcome revealed insights into the real-world treatment and complications relevant to patients with CD and highlights that this disease remains a concern that may require additional treatment strategies in the Brazilian public healthcare system.

Indexed as

Anti-tumor necrosis factorConventional therapyCrohn’s diseaseIntestinal complicationsPublic healthcare system

Identifiers

PMID37274050
PMCPMC10237144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.